Wealth Alliance Advisory Group LLC acquired a new stake in shares of Haemonetics Co. (NYSE:HAE) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 2,000 shares of the medical instruments supplier’s stock, valued at approximately $247,000.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HAE. Quadrant Capital Group LLC boosted its stake in Haemonetics by 708.8% in the 1st quarter. Quadrant Capital Group LLC now owns 647 shares of the medical instruments supplier’s stock valued at $54,000 after buying an additional 567 shares in the last quarter. Welch & Forbes LLC acquired a new position in Haemonetics in the second quarter worth $241,000. Advisor Group Inc. boosted its stake in Haemonetics by 614.5% in the fourth quarter. Advisor Group Inc. now owns 2,022 shares of the medical instruments supplier’s stock worth $203,000 after purchasing an additional 1,739 shares in the last quarter. Squarepoint Ops LLC acquired a new position in Haemonetics in the fourth quarter worth $203,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in Haemonetics in the first quarter worth $203,000. Institutional investors and hedge funds own 98.79% of the company’s stock.
In related news, SVP Jacqueline Scanlan sold 3,646 shares of the company’s stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $112.49, for a total value of $410,138.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Christopher Simon sold 57,587 shares of the company’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $94.51, for a total value of $5,442,547.37. The disclosure for this sale can be found here. Insiders sold 105,754 shares of company stock valued at $10,455,709 in the last quarter. 1.32% of the stock is currently owned by corporate insiders.
A number of equities analysts have commented on the company. TheStreet raised Rent-A-Center from a “c” rating to a “b-” rating in a research note on Tuesday, May 7th. Barrington Research set a $22.00 price objective on The Hackett Group and gave the stock a “buy” rating in a research note on Wednesday, May 8th. Raymond James reissued a “sell” rating on shares of Inter Pipeline in a research note on Tuesday, May 14th. Finally, Zacks Investment Research lowered Glu Mobile from a “buy” rating to a “hold” rating in a research note on Tuesday, April 9th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Haemonetics currently has an average rating of “Buy” and an average price target of $118.60.
NYSE HAE traded up $0.76 on Friday, reaching $123.67. The company had a trading volume of 202,985 shares, compared to its average volume of 310,520. The company has a 50 day moving average of $117.52. The company has a market capitalization of $6.40 billion, a PE ratio of 51.74, a price-to-earnings-growth ratio of 3.16 and a beta of 0.82. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.62 and a current ratio of 2.44. Haemonetics Co. has a 52 week low of $80.24 and a 52 week high of $125.66.
Haemonetics (NYSE:HAE) last released its quarterly earnings data on Tuesday, May 7th. The medical instruments supplier reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.06. The business had revenue of $249.30 million during the quarter, compared to the consensus estimate of $250.62 million. Haemonetics had a return on equity of 18.88% and a net margin of 5.69%. The firm’s revenue was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.43 earnings per share. As a group, equities research analysts predict that Haemonetics Co. will post 2.93 earnings per share for the current fiscal year.
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Further Reading: The primary rules of Elliott Wave theory
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.